TABLE 6.
Univariable and multivariable Cox proportional hazard regression models of 5‐year OS among 629 cT4b tumors undergoing definitive treatment.
| Univariable | Multivariable | ||||
|---|---|---|---|---|---|
| N | HR (95% CI) | p‐value | aHR a (95% CI) | p‐value | |
| Age at diagnosis (years) | 387 | 1.02 (1.01–1.03) | <.001 | 1.02 (1.01–1.03) | .004 |
| Sex | |||||
| Male | Ref | ||||
| Female | 0.97 (0.78–1.22) | .815 | |||
| Race | |||||
| White | Ref | ||||
| Black | 0.86 (0.59–1.26) | .438 | |||
| Other | 0.64 (0.36–1.11) | .110 | |||
| CDCS | |||||
| 0 | Ref | ||||
| ≥1 | 0.97 (0.73–1.30) | .852 | |||
| Histology | |||||
| Adenocarcinoma | 95 | Ref | Ref | ||
| Adenoid cystic carcinoma | 73 | 0.92 (0.66–1.30) | .641 | 0.85 (0.54–1.33) | .479 |
| Neuroendocrine carcinoma | 57 | 0.82 (0.55–1.23) | .337 | 0.77 (0.46–1.28) | .308 |
| Mucoepidermoid carcinoma | 6 | 3.19 (1.64–6.22) | .001 | 2.06 (0.86–4.94) | .105 |
| Melanoma | 30 | 2.15 (1.44–3.21) | <.001 | 1.58 (0.92–2.72) | .095 |
| Esthesioneuroblastoma | 26 | 0.50 (0.30–0.83) | .008 | 0.60 (0.28–1.30) | .194 |
| Undifferentiated carcinoma | 101 | 1.15 (0.83–1.60) | .410 | 1.20 (0.81–1.79) | .364 |
| Primary site | |||||
| Nasal cavity | 136 | Ref | |||
| Accessory sinus | 237 | 1.27 (1.00–1.61) | .049 | 1.38 (1.00–1.90) | .051 |
| Nasopharynx | 15 | 0.72 (0.39–1.35) | .307 | 0.39 (0.15–1.00) | .050 |
| Tumor diameter (cm) | 387 | 1.02 (1.00–1.04) | .021 | 1.02 (1.00–1.04) | .036 |
| Clinical nodal metastasis | |||||
| No | Ref | ||||
| Yes | 1.23 (0.87–1.72) | 0.240 | |||
| Treatment | |||||
| Surgical resection + additional therapy | 315 | 0.70 (0.54–0.91) | .008 | 0.64 (0.45–0.91) | .014 |
| Definitive RT/CRT | 73 | Ref | Ref |
Abbreviations: aHR, adjusted hazard ratio; CDCS, Charlson–Deyo comorbidity score; CI, confidence interval; CRT, chemoradiotherapy; HR, hazard ratio; OS, overall survival; RT, radiotherapy. Bolded values indicate statistically significant results (p<0.05).
a
N = 387; number of uncensored deaths: 192.